AstraZeneca and Merck & Co.’s Lynparza helped patients with advanced pancreatic cancer who carry BRCA gene mutations go nearly twice as long without their disease worsening than those who received a placebo, according to data from a late-stage clinical trial.
Researchers with the NYU School of Medicine and the University of Michigan identified a gene called ATDC that is necessary for the development of pancreatic cancer.
AbbVie is slashing 178 jobs from the company’s Stemcentrx subsidiary in South San Francisco.
BioLineRx Ltd. announced the expansion of its immuno-oncology collaboration with Merck & Co. Inc. for the support of a Phase 2a program investigating BioLineRx’s BL-8040 in combination with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) in patients with metastatic pancreatic cancer.
A study published today by the Pancreatic Cancer Action Network, Perthera Inc., and colleagues in the AACR journal Clinical Cancer Research found for the first time that precision medicine can improve outcomes and provide clinically meaningful information to pancreatic cancer patients.
Lumicell Inc. provided an update on the company’s development strategy for its LUM system pipeline including plans to initiate its pivotal trial in breast cancer as well as expansion of its clinical studies in four other solid tumor cancers.
Pancreatic Cancer Action Network (PanCAN) grantee George Miller, MD, and his research team at NYU Langone Medical Center discovered a novel and potentially targetable way that pancreatic cancer cells hide themselves from the immune system. The findings, published in the journal Nature Medicine, have the potential to broach a new era of effective immunotherapies for pancreatic cancer.
BONITA, CA–(Marketwired – August 17, 2015) – PharmaCyte Biotech Inc. (OTCQB: PMCB) has made a name for itself with the company’s potentially game-changing pancreatic cancer treatment, and also as the […]
